RxDoctor Payments Data

Ricardo Colacioppo, MD

Cardiovascular Disease · San Juan, PRNPI 1023217775

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,560 of the $13,691 with a category attached, or 77.1%. 23 manufacturers reported payments, led by AstraZeneca at 28.6% of the total. Reporting peaked in 2020 at $3,236 and has fallen 64.2% since, to $1,159 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,691in general payments, 2019–2025

Across 222 payments — averaging $61.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Boehringer Ingelheim$2K
  • Amgen$1K
  • Boston Scientific$1K
  • Johnson & Johnson$832
  • E.r. Squibb & Sons, L.L.C.$813
  • plus $4K from 17 others

What the payments were for

  • Speaking & faculty fees$3,10023%
  • Food & beverage$10,56077%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,691 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$53,953
Medicare patients
187
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban444$324,904
FarxigaDapagliflozin Propanediol240$176,357
XareltoRivaroxaban189$144,254
EntrestoSacubitril/Valsartan109$96,490
JanuviaSitagliptin Phosphate58$42,008
JardianceEmpagliflozin54$41,675
Xigduo XrDapaglifloz Propaned/Metformin58$41,634
JanumetSitagliptin Phos/Metformin Hcl44$33,273
Candesartan Cilexetil387$32,115
Synjardy XrEmpagliflozin/Metformin Hcl44$28,165
SynthroidLevothyroxine Sodium380$25,273
BrilintaTicagrelor44$22,315
Janumet XrSitagliptin Phos/Metformin Hcl34$18,174
TradjentaLinagliptin19$17,996
Repatha SureclickEvolocumab29$16,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8$324,904444 claims
AstraZenecaFarxiga, Brilinta$3,911$198,672284 claims
Johnson & JohnsonXarelto$832$144,254189 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy, Glyxambi$2,000$125,318171 claims
MerckJanuvia, Janumet, Janumet Xr$406$93,455136 claims
Novo NordiskOzempic$148$16,20617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →